US 12,005,129 B2
Imaging compositions
Jian Yang, Arlington, TX (US); Dingying Shan, State College, PA (US); and Nanyin Zhang, State College, PA (US)
Assigned to THE PENN STATE RESEARCH FOUNDATION, University Park, PA (US)
Appl. No. 16/337,501
Filed by THE PENN STATE RESEARCH FOUNDATION, University Park, PA (US)
PCT Filed Oct. 6, 2017, PCT No. PCT/US2017/055509
§ 371(c)(1), (2) Date Mar. 28, 2019,
PCT Pub. No. WO2018/067913, PCT Pub. Date Apr. 12, 2018.
Claims priority of provisional application 62/404,792, filed on Oct. 6, 2016.
Prior Publication US 2019/0282713 A1, Sep. 19, 2019
Int. Cl. A61K 9/00 (2006.01); A61K 49/00 (2006.01); A61K 49/08 (2006.01); A61K 49/10 (2006.01); A61K 49/12 (2006.01)
CPC A61K 49/126 (2013.01) [A61K 49/0002 (2013.01); A61K 49/0054 (2013.01); A61K 49/085 (2013.01); A61K 49/105 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A composition comprising:
a polymer or oligomer formed from first reacting:
a) one or more monomers of Formula (A1) and optionally one or more monomers of Formula (A2);
b) one or more monomers of Formula (B1) or (B2);
c) one or more monomers of Formula (F);
d) one or more monomers comprising an MRI contrast agent of Formula (J1), (J2), (J3), (J4), (J5), or (J6), and
optionally one or more other reactants or monomers;
such that the polymer or oligomer has the one or more monomers comprising an MRI contrast agent as a part of a backbone of the polymer or oligomer,
wherein the one or more monomers comprising an MRI contrast agent participate in a condensation polymerization reaction to form the polymer or oligomer;
wherein the formed polymer or oligomer is then crosslinked to form a polymer network,

OG Complex Work Unit Chemistry
HO-[M]-OH  (J1),
HOOC-[M]-COOH  (J2),
H2N-[M]-NH2  (J3),
HO-[M]-COOH  (J4),
HO-[M]-NH2  (J5),
HOOC-[M]-NH2  (J6),
wherein X1, X2, and X3 are each independently O or NH;
R1, R2, and R3 are each independently H, a C1 to C22 alkyl or alkenyl group, or M+;
R4 is H, a C1 to C22 alkyl or alkenyl group, or M+;
R5 is C(O)R23;
M+ is a monovalent metal cation;
R6 is H, NH2, OH, OCH3, OCH2CH3, CH3, or CH2CH3;
R7 is H or a C1 to C23 alkyl or alkenyl group;
R8 is H, a C3 to C22 alkyl or alkenyl group, CH2CH2OH, or CH2CH2NH2;
R15 is an amino acid side chain;
R23 is a C14 to C22 alkyl or alkenyl group;
[M] is a metal-containing portion of the MRI contrast agent;
wherein n is integer ranging from 2 to 20 and
m is integer ranging from 1 to 20.